Loading...
XTAEALMD
Market cap8mUSD
Dec 24, Last price  
33.50ILS
1D
-9.46%
1Q
-16.25%
Jan 2017
-71.05%
IPO
-98.70%
Name

Allmed Solutions Ltd

Chart & Performance

D1W1MN
XTAE:ALMD chart
P/E
2,263.95
P/S
—
EPS
0.01
Div Yield, %
0.00%
Shrs. gr., 5y
-72.62%
Rev. gr., 5y
16.57%
Revenues
0k
2,563,0002,669,0004,701,0004,916,0005,178,0007,353,0007,703,0009,279,00011,147,0009,719,0005,545,00000
Net income
1m
P
-14,067,000-29,787,000-50,005,000-24,644,000-20,932,000-23,917,000-22,679,000-20,175,00021,988,000-10,893,0001,457,000-11,193,0001,422,000
CFO
7m
P
-13,097,000-29,374,000-13,407,000-19,026,000-15,874,000-17,271,000-18,417,000-16,024,000-12,329,000-8,817,000-5,477,000-10,215,0007,136,000
Earnings
Jan 14, 2025

Profile

Allium Medical Solutions Ltd. develops, manufactures, and sells long-term, fully covered, expandable, and retrievable stents for the treatment of the various obstructions in the urinary and GI tract in Israel and internationally. The company offers ureteric, bulbar, triangular and round prostatic, and biliary stents. Allium Medical Solutions Ltd. is based in Caesarea, Israel.
URL
https://www.allium-medical.com/
IPO date
Feb 01, 2007
Employees
19
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,545
-42.95%
Cost of revenue
12,072
2,918
5,003
Unusual Expense (Income)
NOPBT
(12,072)
(2,918)
542
NOPBT Margin
9.77%
Operating Taxes
(947)
1,246
Tax Rate
229.89%
NOPAT
(12,072)
(1,971)
(704)
Net income
1,422
-112.70%
(11,193)
-868.22%
1,457
-113.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,387
344
BB yield
-56,628.48%
-0.97%
Debt
Debt current
334
195
296
Long-term debt
1,416
1,141
414
Deferred revenue
Other long-term liabilities
148
154
Net debt
(55,351)
(26,395)
(24,308)
Cash flow
Cash from operating activities
7,136
(10,215)
(5,477)
CAPEX
(119)
(438)
(44)
Cash from investing activities
(21,597)
2,184
12,543
Cash from financing activities
(288)
12,015
(539)
FCF
(11,436)
(3,416)
28,568
Balance
Cash
57,101
21,032
15,606
Long term investments
6,699
9,412
Excess cash
57,101
27,731
24,741
Stockholders' equity
(203,092)
(204,686)
(198,540)
Invested Capital
259,941
259,463
251,361
ROIC
ROCE
1.03%
EV
Common stock shares outstanding
112
88
80,616
Price
0.37
49.40%
0.25
-43.15%
0.44
-18.28%
Market cap
42
90.20%
22
-99.94%
35,310
-17.98%
EV
(52,758)
(23,932)
12,908
EBITDA
(11,596)
(2,368)
1,604
EV/EBITDA
4.55
10.11
8.05
Interest
46
96
Interest/NOPBT
17.71%